J. Bendell

R. Herbst, E. Rasmussen, L. Paz-Ares, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Randomized phase II study of modified FOLFOX-6 in combination with ramucirumab or icrucumab as second-line therapy in patients with metastatic colorectal cancer after disease progression on first-line irinotecan-based therapy.

J. Bendell, T. Alcindor, P. Tang, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Safety and effectiveness of bevacizumab treatment for metastatic colorectal cancer: final results from the Avastin(®) Registry - Investigation of Effectiveness and Safety (ARIES) observational cohort study.

A. Grothey, H. Hurwitz, T. Bekaii-Saab, 2014, Clinical oncology (Royal College of Radiologists (Great Britain)).

Phase II trial of FOLFOX6, bevacizumab, and cetuximab in the first-line treatment of metastatic colorectal cancer.

J. Hainsworth, J. Bendell, H. Burris, 2010, Clinical advances in hematology & oncology : H&O.

Bevacizumab exposure beyond first disease progression in patients with metastatic colorectal cancer: analyses of the ARIES observational cohort study

A. Grothey, H. Hurwitz, T. Bekaii-Saab, 2014, Pharmacoepidemiology and drug safety.

Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors

H. Hurwitz, J. Bendell, H. Pang, 2014, Investigational New Drugs.

Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trial.

P. Philip, S. Alberts, Z. Wainberg, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Clinical outcomes in bevacizumab (BV)-treated patients (pts) with metastatic colorectal cancer (mCRC): Results from ARIES observational cohort study (OCS) and confirmation of BRiTE data on BV beyond progression (BBP).

A. Grothey, H. Hurwitz, T. Bekaii-Saab, 2010 .

Concurrent chemoradiotherapy in resected extrahepatic cholangiocarcinoma.

C. Willett, R. Clough, H. Hurwitz, 2009, International journal of radiation oncology, biology, physics.

Axitinib or bevacizumab plus FOLFIRI or modified FOLFOX-6 after failure of first-line therapy for metastatic colorectal cancer: a randomized phase II study.

C. Tournigand, Z. Wainberg, J. Bendell, 2013, Clinical colorectal cancer.

A phase I study of bevacizumab (B) in combination with everolimus (E) and erlotinib (E) in advanced cancer (BEE)

H. Hurwitz, J. Bendell, G. Blobe, 2011, Cancer Chemotherapy and Pharmacology.

Individual Patient Data Meta-Analysis of FOLFOXIRI Plus Bevacizumab Versus Doublets Plus Bevacizumab as Initial Therapy of Unresectable Metastatic Colorectal Cancer.

T. Gruenberger, H. Hurwitz, J. Bendell, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized, double‐blind, phase two study of ruxolitinib plus regorafenib in patients with relapsed/refractory metastatic colorectal cancer

J. Nemunaitis, J. Bendell, C. Borg, 2018, Cancer medicine.

Donating tissue for research: patient and provider perspectives.

J. Bendell, M. Smith, A. Baer, 2011, Journal of oncology practice.

RTOG 0822: A Phase II Study of Preoperative (PREOP) Chemoradiotherapy (CRT) Utilizing IMRT in Combination with Capecitabine (C) and Oxaliplatin (O) for Patients with Locally Advanced Rectal Cancer

J. Bendell, T. Hong, F. Lerma, 2011 .

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts

Amanda R. Campbell, F. Lund-Johansen, Yair Benita, 2016, Journal for ImmunoTherapy of Cancer.

A multicenter, open-label, expanded phase 2 study to evaluate the safety and efficacy of etirinotecan pegol, a polymer conjugate of irinotecan, in women with recurrent platinum-resistant or refractory ovarian cancer.

G. Rustin, I. Vergote, J. Bendell, 2017, Gynecologic oncology.

A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors

Suzanne F. Jones, G. Shapiro, S. Shreeve, 2015, Investigational New Drugs.

Phase I study of weekly paclitaxel in combination with pazopanib and lapatinib in advanced solid malignancies

A. Tan, J. Bendell, J. Infante, 2014, British Journal of Cancer.

Safety, pharmacokinetics and pharmacodynamics of the anti-A33 fully-human monoclonal antibody, KRN330, in patients with advanced colorectal cancer.

Suzanne F. Jones, J. Berlin, E. Chan, 2013, European journal of cancer.

Randomized open-label phase 2 study of MM-111 and paclitaxel (PTX) with trastuzumab (TRAS) in patients with HER2-expressing carcinomas of the distal esophagus, gastroesophageal (GE) junction, and stomach who have failed front-line metastatic or locally ad

Y. Bang, J. Bendell, M. Alsina, 2014 .

Single agent activity of ZW25, a HER2-targeted bispecific antibody, in heavily pretreated HER2-expressing cancers.

J. Ajani, J. Mayordomo, F. Meric-Bernstam, 2018 .

Phase I Study of LY2606368, a Checkpoint Kinase 1 Inhibitor, in Patients With Advanced Cancer.

Suzanne F. Jones, R. Kurzrock, F. Janku, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I/II study to assess safety, pharmacokinetics, and efficacy of the oral MEK 1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral BRAF inhibitor GSK2118436 (GSK436).

K. Flaherty, G. Shapiro, R. Kurzrock, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Updates in the management of esophageal and gastric cancers

J. Bendell, K. Bullock, 2008 .

A Phase II Randomized Trial (GO27827) of First-Line FOLFOX Plus Bevacizumab with or Without the MET Inhibitor Onartuzumab in Patients with Metastatic Colorectal Cancer.

H. Koeppen, L. Hart, J. Bendell, 2017, The oncologist.

Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.

P. Gibbs, L. Diaz, E. Van Cutsem, 2020, The New England journal of medicine.

Phase 1 cohort expansion study of LY3023414, a dual PI3K/mTOR inhibitor, in patients with advanced mesothelioma

M. Zauderer, A. Varghese, J. Bendell, 2021, Investigational New Drugs.

A randomized, placebo-controlled, phase I/II study of tivantinib (ARQ 197) in combination with cetuximab and irinotecan in patients (pts) with KRAS wild-type (WT) metastatic colorectal cancer (CRC) who had received previous front-line systemic therapy.

S. Barni, L. Hart, J. Bendell, 2013 .

Meta-analysis examining overall survival in patients with pancreatic cancer treated with second-line 5-fluorouracil and oxaliplatin-based therapy after failing first-line gemcitabine-containing therapy: effect of performance status and comparison with other regimens

Myung Ah Lee, J. Hecht, Z. Wainberg, 2020, BMC Cancer.

A Randomized, Double‐Blinded, Phase II Trial of Gemcitabine and Nab‐Paclitaxel Plus Apatorsen or Placebo in Patients with Metastatic Pancreatic Cancer: The RAINIER Trial

M. Tempero, J. Bendell, L. Debusk, 2017, The oncologist.

Combination of the mTOR Inhibitor Ridaforolimus and the Anti-IGF1R Monoclonal Antibody Dalotuzumab: Preclinical Characterization and Phase I Clinical Trial

J. Baselga, J. Bendell, I. Braña, 2014, Clinical Cancer Research.

Safety and Efficacy of Durvalumab and Tremelimumab Alone or in Combination in Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma

Y. Bang, M. Rebelatto, H. Lenz, 2019, Clinical Cancer Research.

Current perspectives on anal cancer.

D. Ryan, J. Bendell, 2003, Oncology.

Safety and efficacy of the anti-CD73 monoclonal antibody (mAb) oleclumab ± durvalumab in patients (pts) with advanced colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), or EGFR-mutant non-small cell lung cancer (EGFRm NSCLC).

J. Desai, S. Clarke, Dong-Wan Kim, 2021 .

A First-in-Human Phase I Study to Evaluate the ERK1/2 Inhibitor GDC-0994 in Patients with Advanced Solid Tumors

Sandra M. Sanabria-Bohórquez, P. LoRusso, J. Soria, 2016, Clinical Cancer Research.

Phase 1 Expansion Cohort of Ramucirumab Plus Pembrolizumab in Advanced Treatment-Naive NSCLC

Hong Wang, R. Herbst, L. Paz-Ares, 2021 .

Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors.

J. Desai, B. Goh, B. Solomon, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

ARC-8: Phase I/Ib study to evaluate safety and tolerability of AB680 + chemotherapy + zimberelimab (AB122) in patients with treatment-naive metastatic pancreatic adenocarcinoma (mPDAC).

Z. Wainberg, J. Bendell, N. Giafis, 2021 .

Abstract CT026: Evidence of immune activation in the first-in-human Phase Ia dose escalation study of the adenosine 2a receptor antagonist, AZD4635, in patients with advanced solid tumors

B. Linghu, C. Drake, J. Bendell, 2019, Clinical Trials.

90PDPreviously treated advanced NSCLC cohort from a multi-disease phase 1 study of ramucirumab (R) plus pembrolizumab (P): Efficacy and safety data

R. Herbst, L. Paz-Ares, J. Bendell, 2017 .

Interim safety and clinical activity in patients (pts) with advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma from a multicohort phase 1 study of ramucirumab (R) plus pembrolizumab (P).

R. Herbst, C. Fuchs, J. Bendell, 2017 .

KRN330, a fully human antibody against A33, in combination with irinotecan for patients with metastatic colorectal cancer (mCRC).

J. Berlin, J. Marshall, J. Bendell, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abstract 2431: In vivo antibody binding to tumor in xenograft rodent models and colorectal cancer patients treated with anti-A33 antibody KRN330

Suzanne F. Jones, J. Berlin, E. Chan, 2010 .

Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gemcitabine (SEQUOIA)

Joon-Oh Park, R. Greil, E. Van Cutsem, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Initial results from ARIES, a multi-indication bevacizumab (BV) observational cohort study (OCS): Characteristics of metastatic colorectal cancer (mCRC) patients (pts) receiving BV and chemotherapy (CT) in 2nd line

D. Sargent, A. Grothey, T. Bekaii-Saab, 2008 .

Phase I/II study of E7050 (golvantinib) in combination with sorafenib in patients (pts) with advanced hepatocellular carcinoma (HCC): Phase I results.

J. Machiels, J. Bendell, B. O'Neil, 2013 .

Phase Ib dose-escalation trial evaluating c-MET inhibitor ARQ 197 administered in combination with gemcitabine to patients (pts) with advanced solid tumors.

Suzanne F. Jones, J. Bendell, L. Camacho, 2010 .

Single-arm, phase 2 study of regorafenib plus nivolumab in patients with mismatch repair-proficient (pMMR)/microsatellite stable (MSS) colorectal cancer (CRC).

N. Sharma, M. Fakih, J. Bendell, 2021 .

Efficacy and tolerability in an open-label phase I/II study of MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in combination in patients (pts) with BRAF V600E mutated colorectal cancer (CRC).

R. Bernards, C. Atreya, J. Schellens, 2014 .

A phase I study of gemcitabine + dasatinib (gd) or gemcitabine + dasatinib + cetuximab (GDC) in refractory solid tumors

H. Hurwitz, J. Bendell, D. Niedzwiecki, 2019, Cancer Chemotherapy and Pharmacology.

Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer.

Gary Middleton, Takayuki Yoshino, Chloe E Atreya, 2018, Cancer discovery.

Phase 1b/II study of cancer stemness inhibitor napabucasin (BBI-608) in combination with FOLFIRI +/- bevacizumab (bev) in metastatic colorectal cancer (mCRC) patients (pts).

A. Grothey, J. Bendell, H. Pitot, 2017 .

Phase 2 results: Encorafenib (ENCO) and cetuximab (CETUX) with or without alpelisib (ALP) in patients with advanced BRAF-mutant colorectal cancer (BRAFm CRC).

J. Desai, J. Schellens, H. Lenz, 2016 .

Phase I study of olaparib plus gemcitabine in patients with advanced solid tumours and comparison with gemcitabine alone in patients with locally advanced/metastatic pancreatic cancer.

J. Bendell, H. Burris, H. Hochster, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Bevacizumab (B) plus everolimus (E) in refractory metastatic colorectal cancer (mCRC).

H. Hurwitz, J. Bendell, G. Blobe, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effectiveness and safety of second-line (2L) irinotecan- and oxaliplatin-based regimens after first-line (1L) bevacizumab (BV)-containing treatment (tx) for metastatic colorectal cancer (mCRC): Results from the ARIES observational cohort study.

A. Grothey, H. Hurwitz, T. Bekaii-Saab, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The PI3K/mTOR inhibitor BEZ235 given twice daily for the treatment of patients (pts) with advanced solid tumors.

Suzanne F. Jones, J. Bendell, H. Burris, 2012 .

A first-in-human phase I study to evaluate GDC-0980, an oral PI3K/mTOR inhibitor, administered QD in patients with advanced solid tumors.

J. Ware, J. Bendell, H. Burris, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

FOLFOXIRI/bevacizumab (bev) versus doublets/bev as initial therapy of unresectable metastatic colorectal cancer (mCRC): A meta-analysis of individual patient data (IPD) from five randomized trials.

T. Gruenberger, H. Hurwitz, J. Bendell, 2020 .

LBA-07Updated Results of the MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E mutated (BRAFm) metastatic colorectal cancer (mCRC)

C. Atreya, M. Ducreux, J. Schellens, 2015 .

Pembrolizumab versus chemotherapy for microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer: The phase 3 KEYNOTE-177 Study.

P. Gibbs, L. Diaz, Ping Yang, 2020, Journal of Clinical Oncology.

Efficacy and circulating tumor DNA (ctDNA) analysis of the BRAF inhibitor dabrafenib (D), MEK inhibitor trametinib (T), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E–mutated (BRAFm) metastatic colorectal cancer (mCRC)

S. Jaeger, C. Atreya, M. Ducreux, 2016 .

Meta-analysis of OS for pancreatic cancer patients receiving 5FU and oxaliplatin-based therapy after failing first-line gemcitabine-containing therapy.

Myung Ah Lee, J. Hecht, Z. Wainberg, 2019, Journal of Clinical Oncology.

Overall survival of PEGylated pegilodecakin with 5-FU/LV and oxaliplatin (FOLFOX) in metastatic pancreatic adenocarcinoma (PDAC).

J. Hecht, Z. Wainberg, K. Papadopoulos, 2018 .

A phase II study of capecitabine, oxaliplatin, and bevacizumab in the treatment of metastatic esophagogastric adenocarcinomas.

H. Hurwitz, J. Bendell, G. Blobe, 2013, The oncologist.

Immediate impact of the FOLFIRINOX phase III data reported at the 2010 ASCO Annual Meeting on prescribing plans of American oncology physicians for patients with metastatic pancreas cancer (MPC).

J. Marshall, J. Bendell, M. Green, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

First-in-HumanStudyofPF-05212384 ( PKI-587 ) , a Small-Molecule , Intravenous , Dual Inhibitor of PI 3 K and mTOR in Patients with Advanced Cancer

G. Shapiro, J. Tabernero, E. Kwak, 2015 .

Abstract LB-65: Towards defining the genetic framework for clinical response to treatment with BYL719, a PI3Kalpha-specific inhibitor.

J. Lehár, L. Garraway, P. Stephens, 2013 .

Abstract A167: First-in-patient study of PF-05212384, a small molecule intravenous dual inhibitor of PI3K and mTOR in patients with advanced cancer: Update on safety, efficacy, and pharmacology.

G. Shapiro, J. Tabernero, E. Kwak, 2011 .

Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced

G. Shapiro, E. Kwak, J. Bendell, 2015 .

LBA-08Results of a phase 1b study of the selective BRAF V600 inhibitor encorafenib in combination with cetuximab alone or cetuximab + alpelisib for treatment of patients with advanced BRAF-mutant metastatic colorectal cancer

S. Jaeger, J. Schellens, H. Lenz, 2015 .

Phase I/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032

D. Jäger, P. Ascierto, P. Ott, 2015, Journal of Immunotherapy for Cancer.

Anal cancer: an overview.

J. Bendell, H. Uronis, 2007, The oncologist.

Safety and activity of nivolumab monotherapy in advanced and metastatic (A/M) gastric or gastroesophageal junction cancer (GC/GEC): Results from the CheckMate-032 study.

P. Ascierto, P. Sharma, P. Ott, 2016 .

Ramucirumab (RAM) plus FOLFOX as front-line therapy (Rx) for advanced gastric or esophageal adenocarcinoma (GE-AC): Randomized, double-blind, multicenter phase 2 trial.

P. Philip, S. Alberts, Z. Wainberg, 2014 .

Abstract 2673: Association of PD-L1 combined positive score and immune gene signatures with efficacy of nivolumab (NIVO) ± ipilimumab (IPI) in patients with metastatic gastroesophageal cancer (mGEC)

P. Sharma, Han Chang, N. Siemers, 2019, Clinical Research (Excluding Clinical Trials).

Antitumor activity of ipatasertib combined with chemotherapy: results from a phase Ib study in solid tumors.

J. Soria, J. Bendell, D. Sampath, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase 1, open-label, dose-escalation, and pharmacokinetic study of STAT3 inhibitor OPB-31121 in subjects with advanced solid tumors

Suzanne F. Jones, E. Rock, R. Kurzrock, 2014, Cancer Chemotherapy and Pharmacology.

KEYNOTE-177: Randomized phase III study of pembrolizumab versus investigator-choice chemotherapy for mismatch repair-deficient or microsatellite instability-high metastatic colorectal carcinoma.

D. Jäger, L. Diaz, J. Bendell, 2017 .

Efficacy and safety of atezolizumab (atezo) and bevacizumab (bev) in a phase Ib study of microsatellite instability (MSI)-high metastatic colorectal cancer (mCRC).

J. Bendell, H. Hochster, K. Iizuka, 2017 .

Abstract 2651: Clinical activity and immune correlates from a phase Ib study evaluating atezolizumab (anti-PDL1) in combination with FOLFOX and bevacizumab (anti-VEGF) in metastatic colorectal carcinoma

P. Hegde, H. Hurwitz, J. Bendell, 2016 .

Clinical activity and safety of cobimetinib (cobi) and atezolizumab in colorectal cancer (CRC).

J. Desai, K. Flaherty, B. Goh, 2016 .

Phase I study of PF-04554878, a second-generation focal adhesion kinase (FAK) inhibitor, in patients with advanced solid tumors.

G. Shapiro, S. Shreeve, Philippe Bédard, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

CD8+ T cell stimulation with pegylated recombinant human IL-10 in the patient with advanced solid tumors - a Phase I study

F. Janku, K. Papadopoulos, J. Bendell, 2015, Journal of Immunotherapy for Cancer.

KEYNOTE-177: Phase III randomized study of pembrolizumab versus chemotherapy for microsatellite instability-high advanced colorectal cancer.

P. Gibbs, Ping Yang, C. Punt, 2021 .

A phase I dose escalation study of NK012, an SN-38 incorporating macromolecular polymeric micelle

Suzanne F. Jones, J. Bendell, H. Burris, 2016, Cancer Chemotherapy and Pharmacology.

A first-in-human, phase l study to evaluate the dual PI3K/mTOR inhibitor GDC-0980 administered QD in patients with advanced solid tumors or non-Hodgkin's lymphoma.

J. Ware, J. Bendell, H. Burris, 2010 .

A phase Ib dose-escalation and cohort-expansion study of safety and activity of the transforming growth factor (TGF) β receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer.

Joon-Oh Park, A. Varghese, D. Melisi, 2019, Journal of Clinical Oncology.

A phase II trial of preoperative chemoradiation therapy plus bevacizumab and erlotinib in the treatment of localized esophageal cancer.

J. Hainsworth, J. Bendell, H. Burris, 2010 .

Abstract CT-01: BYL719, a next generation PI3K alpha specific inhibitor: Preliminary safety, PK, and efficacy results from the first-in-human study

J. Berlin, J. Baselga, D. Juric, 2012 .

Phase I trial of an oral TORC1/TORC2 inhibitor (CC-223) in advanced solid and hematologic cancers.

Suzanne F. Jones, R. Kelley, J. Bendell, 2012 .

Abstract B243: A phase I dose-escalation study of MEK inhibitor MEK162 (ARRY-438162) in patients with advanced solid tumors.

Suzanne F. Jones, K. Papadopoulos, A. Patnaik, 2011 .

Oral PI3 kinase inhibitor BKM120 monotherapy in patients (pts) with advanced solid tumors: An update on safety and efficacy.

J. Baselga, D. Demanse, A. Razak, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I/II, open-label study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) as monotherapy or combined with ipilimumab in advanced or metastatic solid tumors.

P. Sharma, P. Ott, M. Callahan, 2014 .

Analyses of PD-L1 and In ﬂ ammatory Gene Expression Association with Ef ﬁ cacy of Nivolumab (cid:1) Ipilimumab in Gastric Cancer/Gastroesophageal Junction Cancer

P. Sharma, N. Siemers, P. Ott, 2021 .

Safety and Efficacy of Andecaliximab (GS-5745) Plus Gemcitabine and Nab-Paclitaxel in Patients with Advanced Pancreatic Adenocarcinoma: Results from a Phase I Study.

J. Berlin, M. Shah, Sunil Sharma, 2020, The oncologist.

Napabucasin Plus FOLFIRI in Patients With Previously Treated Metastatic Colorectal Cancer: Results From the Open-Label, Randomized Phase III CanStem303C Study.

M. Shah, E. Van Cutsem, J. Tabernero, 2022, Clinical colorectal cancer.

Cancer stemness inhibition and chemosensitization: Phase 1b/II study of cancer stemness inhibitor napabucasin (BBI-608) with FOLFIRI +/- bevacizumab (Bev) administered to colorectal cancer (CRC) patients (pts).

A. Grothey, J. Bendell, H. Pitot, 2017 .

MORPHEUS: A phase Ib/II multi-trial platform evaluating the efficacy and safety of cancer immunotherapy (CIT)-based combinations in patients (pts) with gastric or pancreatic cancer.

J. Ajani, Y. Bang, Y. Janjigian, 2018 .

Preliminary results of a phase I study of bevacizumab (BV) in combination with everolimus (E) in patients with advanced solid tumors.

Daohai Yu, H. Hurwitz, J. Bendell, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Axitinib or bevacizumab (bev) plus FOLFOX or FOLFIRI as second-line therapy in patients (pts) with metastatic colorectal cancer (mCRC).

C. Tournigand, J. Bendell, A. Ricart, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase I Dose-Escalation Study Evaluating the Safety Tolerability and Pharmacokinetics of CUDC-427, a Potent, Oral, Monovalent IAP Antagonist, in Patients with Refractory Solid Tumors

A. Tolcher, F. Peale, K. Papadopoulos, 2016, Clinical Cancer Research.

Upper gastrointestinal tract.

C. Willett, J. Bendell, 2006, Cancer treatment and research.

Ramucirumab plus pembrolizumab in previously treated advanced or metastatic biliary tract cancer: A multi-disease phase 1 study.

R. Herbst, J. Bendell, D. Ferry, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase II study of oxaliplatin (OX), capecitabine (CAP), and bevacizumab (BV) in the treatment of metastatic colorectal cancer.

H. Hurwitz, J. Bendell, G. Blobe, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety, tolerability, and pharmacokinetics of TAK-701, a humanized anti-hepatocyte growth factor (HGF) monoclonal antibody, in patients with advanced nonhematologic malignancies: First-in-human phase I dose-escalation study.

Suzanne F. Jones, J. Bendell, R. Cohen, 2010 .

STEAM: A randomized, open-label, phase 2 trial of sequential and concurrent FOLFOXIRI-bevacizumab (BEV) versus FOLFOX-BEV for the first-line (1L) treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC).

J. Reeves, H. Hurwitz, J. Bendell, 2014 .

Phase I/II study of durvalumab and tremelimumab in patients with unresectable hepatocellular carcinoma (HCC): Phase I safety and efficacy analyses.

M. Rebelatto, M. Borad, G. Abou-Alfa, 2017 .

Phase Ib evaluation of MPDL3280A (anti-PDL1) in combination with bevacizumab (bev) in patients (pts) with metastatic renal cell carcinoma (mRCC).

Suzanne F. Jones, M. Sznol, J. Bendell, 2015 .

Phase Ib/II Study of Enzalutamide with Samotolisib (LY3023414) or Placebo in Patients with Metastatic Castration-Resistant Prostate Cancer

J. Bendell, C. Albany, C. Sweeney, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Abstract P6-12-02: Phase Ib dose-escalation study of an Akt inhibitor ipatasertib (Ipat) in combination with docetaxel (Doc) or paclitaxel (Pac) in patients (pts) with metastatic breast cancer (MBC)

Sandra M. Sanabria-Bohórquez, J. Soria, J. Bendell, 2015 .

Abstract A252: A phase 1 study of ARRY-382, an oral inhibitor of colony-stimulating factor-1 receptor (CSF1R), in patients with advanced or metastatic cancers.

Suzanne F. Jones, A. Tolcher, K. Wood, 2013 .

Safety and activity of IT-139, a ruthenium-based compound, in patients with advanced solid tumours: a first-in-human, open-label, dose-escalation phase I study with expansion cohort

Suzanne F. Jones, D. V. Von Hoff, G. Weiss, 2016, ESMO Open.

First-in-human study of the antibody DR5 agonist DS-8273a in patients with advanced solid tumors

M. Maitland, J. Bendell, G. Senaldi, 2017, Investigational New Drugs.

Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed.

J. Nemunaitis, H. Hurwitz, Z. Wainberg, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer

P. Ascierto, P. Sharma, F. D. De Braud, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial.

D. Jäger, P. Ascierto, P. Sharma, 2016, The Lancet. Oncology.

NKP-1339: Maximum tolerated dose defined for first-in-human GRP78 targeted agent.

Suzanne F. Jones, Dana Statton Thompson, G. Weiss, 2012 .

A phase I dose-escalation study of NKP-1339 in patients with advanced solid tumors refractory to treatment.

D. V. Von Hoff, G. Weiss, J. Bendell, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Detection of Novel Actionable Genetic Changes in Salivary Duct Carcinoma Helps Direct Patient Treatment

Julie M. Batten, A. Iafrate, K. Flaherty, 2012, Clinical Cancer Research.

Dual TORK/DNA-PK inhibition blocks critical signaling pathways in chronic lymphocytic leukemia.

M. Kersten, M. Hallek, S. Fernandes, 2016, Blood.

Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.

K. Flaherty, R. Kurzrock, L. Hart, 2012, The Lancet. Oncology.

Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma

Suzanne F. Jones, Fabien Gaire, P. Hegde, 2016, Nature Communications.

Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors.

Jordi Rodon, Diana Birle, J. Baselga, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors

M. Zauderer, R. Yeh, J. Ware, 2016, Clinical Cancer Research.

Phase Ib Study of Buparlisib plus Trastuzumab in Patients with HER2-Positive Advanced or Metastatic Breast Cancer That Has Progressed on Trastuzumab-Based Therapy

Guy Jerusalem, Cristina Saura, J. Baselga, 2014, Clinical Cancer Research.

First-in-human phase I/II study of CYT-0851, a first-in-class inhibitor of RAD51-mediated homologous recombination in patients with advanced solid and hematologic cancers.

R. Advani, J. Bendell, P. Munster, 2021 .

Evaluation of Prexasertib, a Checkpoint Kinase 1 Inhibitor, in a Phase Ib Study of Patients with Squamous Cell Carcinoma

Suzanne F. Jones, F. Meric-Bernstam, J. Bendell, 2018, Clinical Cancer Research.

Safety and Clinical Activity of a New Anti-PD-L1 Antibody as Monotherapy or Combined with Targeted Therapy in Advanced Solid Tumors: The PACT Phase Ia/Ib Trial

Y. Bang, A. Italiano, A. Patnaik, 2020, Clinical Cancer Research.

A phase II study of antibody-drug conjugate, TAK-264 (MLN0264) in previously treated patients with advanced or metastatic pancreatic adenocarcinoma expressing guanylyl cyclase C

Huyuan Yang, P. Enzinger, J. Bendell, 2017, Investigational New Drugs.

Phase II study of the antibody-drug conjugate TAK-264 (MLN0264) in patients with metastatic or recurrent adenocarcinoma of the stomach or gastroesophageal junction expressing guanylyl cyclase C

J. Bendell, M. Alsina, W. Messersmith, 2017, Investigational New Drugs.

Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial.

J. Lacy, S. Park, Y. Bang, 2020, The Lancet. Oncology.

Safety, Antitumor Activity, and Immune Activation of Pegylated Recombinant Human Interleukin-10 (AM0010) in Patients With Advanced Solid Tumors.

P. Ott, K. Papadopoulos, J. Bendell, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I, First‐in‐Human, Dose‐Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Vorolanib in Patients with Advanced Solid Tumors

C. Liang, J. Bendell, H. Arkenau, 2018, The oncologist.

A phase 1 study of the sachet formulation of the oral dual PI3K/mTOR inhibitor BEZ235 given twice daily (BID) in patients with advanced solid tumors

Suzanne F. Jones, J. Bendell, H. Burris, 2015, Investigational new drugs.

Relative bioavailability of pediatric oral solution and tablet formulations of trametinib in adult patients with solid tumors

Suzanne F. Jones, J. Bendell, H. Burris, 2015, Clinical pharmacology in drug development.

Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors

J. Bendell, I. Braña, L. Siu, 2014, Investigational New Drugs.

A phase I study of bevacizumab, everolimus and panitumumab in advanced solid tumors

H. Hurwitz, R. Riedel, J. Bendell, 2012, Cancer Chemotherapy and Pharmacology.

Adjuvant Therapy of Pancreatic Cancer

C. Willett, J. Bendell, B. Czito, 2007, Cancer journal.

A phase II trial of preoperative concurrent chemotherapy/radiation therapy plus bevacizumab/erlotinib in the treatment of localized esophageal cancer.

J. Hainsworth, J. Bendell, H. Burris, 2012, Clinical advances in hematology & oncology : H&O.

Targeted Therapy in Rectal Cancer August

Jeffrey W. Clark, R. Jain, C. Willett, 2017 .

Circulating copper and zinc levels and risk of hepatobiliary cancers in Europeans

Suzanne F. Jones, A. Tolcher, R. Finn, 2017, British Journal of Cancer.

Evolving Diagnostic and Treatment Strategies for Pancreatic Neuroendocrine Tumors

L. Kvols, J. Bendell, J. Picus, 2011, Journal of hematology & oncology.

Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer.

C. Atreya, R. Kurzrock, D. Ryan, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

BRAF-Mutant Transcriptional Subtypes Predict Outcome of Combined BRAF, MEK, and EGFR Blockade with Dabrafenib, Trametinib, and Panitumumab in Patients with Colorectal Cancer

J. Millholland, C. Atreya, E. Van Cutsem, 2020, Clinical Cancer Research.

First-In-Human Phase I Study Of A Dual mTOR Kinase And DNA-PK Inhibitor (CC-115) In Advanced Malignancy

David C. Smith, T. Mikkelsen, T. Cloughesy, 2019, Cancer management and research.

A First-in-Human Phase 1 Study of LY3023414, an Oral PI3K/mTOR Dual Inhibitor, in Patients with Advanced Cancer

A. Varghese, D. Hyman, J. Bendell, 2018, Clinical Cancer Research.

Phase I expansion trial of an oral TORC1/TORC2 inhibitor (CC-223) in advanced solid tumors.

T. Cloughesy, P. Mischel, J. Nemunaitis, 2013 .

A phase Ib study of the Akt inhibitor GDC-0068 with docetaxel (D) or mFOLFOX-6 (F) in patients (pts) with advanced solid tumors.

Suzanne F. Jones, J. Tabernero, J. Soria, 2012 .

A first-in-human phase I study of BKM120, an oral pan-class I PI3K inhibitor, in patients (pts) with advanced solid tumors.

J. Baselga, D. Birle, D. Demanse, 2010 .

A phase Ib open-label dose escalation study of the safety, pharmacokinetics, and pharmacodynamics of cobimetinib (GDC-0973) and ipatasertib (GDC-0068) in patients with locally advanced or metastatic solid tumors

Sandra M. Sanabria-Bohórquez, G. Shapiro, P. LoRusso, 2020, Investigational New Drugs.

First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer

G. Shapiro, J. Tabernero, E. Kwak, 2015, Clinical Cancer Research.

A first-in-human phase Ib study to evaluate the MEK inhibitor GDC-0973, combined with the pan-PI3K inhibitor GDC-0941, in patients with advanced solid tumors.

M. Belvin, G. Shapiro, P. LoRusso, 2012 .

11LBA Phase I study of the selective BRAFV600 inhibitor encorafenib (LGX818) combined with cetuximab and with or without the α-specific PI3K inhibitor alpelisib (BYL719) in patients with advanced BRAF mutant colorectal cancer

S. Jaeger, J. Schellens, H. Lenz, 2014 .

Therapeutic targeting of SLC6A8 creatine transporter inhibits KRAS mutant and wildtype colon cancer and modulates human creatine levels

S. Tavazoie, Shugaku Takeda, K. Manova-Todorova, 2021, bioRxiv.

CheckMate-032: Phase I/II, open-label study of safety and activity of nivolumab (nivo) alone or with ipilimumab (ipi) in advanced and metastatic (A/M) gastric cancer (GC).

P. Ascierto, P. Sharma, P. Ott, 2016 .

A randomized, placebo‐controlled, phase 1/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with wild‐type KRAS who have received first‐line systemic therapy

S. Barni, L. Hart, J. Bendell, 2016, International journal of cancer.

Clinical Cancer Advances 2021: ASCO's Report on Progress Against Cancer.

Sonali M. Smith, R. Schilsky, H. Mackay, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pegilodecakin as monotherapy or in combination with anti‐PD‐1 or tyrosine kinase inhibitor in heavily pretreated patients with advanced renal cell carcinoma: Final results of cohorts A, G, H and I of IVY Phase I study

K. Papadopoulos, J. Bendell, A. Naing, 2021, International journal of cancer.

A phase I study of panobinostat in combination with gemcitabine in the treatment of solid tumors.

Suzanne F. Jones, J. Bendell, H. Burris, 2011, Clinical advances in hematology & oncology : H&O.

A randomized phase II trial of nab‐paclitaxel and gemcitabine with tarextumab or placebo in patients with untreated metastatic pancreatic cancer

A. Bullock, J. Bendell, J. Dupont, 2019, Cancer medicine.

Central nervous system metastases in women who receive trastuzumab‐based therapy for metastatic breast carcinoma

E. Winer, M. Rue, R. Gelman, 2003, Cancer.

Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with locally advanced or metastatic breast cancer.

Suzanne F. Jones, L. Hart, J. Bendell, 2014, Journal of Clinical Oncology.

A first-in-human phase I study of the oral Notch inhibitor, LY900009, in patients with advanced cancer.

Suzanne F. Jones, J. Bendell, H. Burris, 2016, European journal of cancer.

Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with pemetrexed in patients with advanced solid tumors

Chun-Fang Xu, S. Novello, J. Bendell, 2013, Investigational New Drugs.

Phase I trial of a dual TOR kinase and DNA-PK inhibitor (CC-115) in advanced solid and hematologic cancers.

David C. Smith, T. Mikkelsen, T. Cloughesy, 2016 .

A phase I trial of oral administration of panobinostat in combination with paclitaxel and carboplatin in patients with solid tumors

Suzanne F. Jones, J. Bendell, H. Burris, 2012, Cancer Chemotherapy and Pharmacology.

Ruxolitinib + capecitabine in advanced/metastatic pancreatic cancer after disease progression/intolerance to first-line therapy: JANUS 1 and 2 randomized phase III studies

M. Hidalgo, E. Van Cutsem, H. Hurwitz, 2018, Investigational New Drugs.

A phase I dose‐escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC‐223 in patients with advanced solid tumors or multiple myeloma

Suzanne F. Jones, Y. Liu, P. Mischel, 2015, Cancer.

Phase I study of XL281 (BMS-908662), a potent oral RAF kinase inhibitor, in patients with advanced solid tumors

P. LoRusso, G. Schwartz, J. Bendell, 2015, Investigational New Drugs.

A Phase 2 Study of the Hsp90 Inhibitor AUY922 as Treatment for Patients with Refractory Gastrointestinal Stromal Tumors

J. Bendell, H. Burris, D. Spigel, 2016, Cancer investigation.

Safety, Efficacy, and Biomarker Results from a Phase Ib Study of the Anti-DKK1 Antibody DKN-01 in Combination with Pembrolizumab in Advanced Esophagogastric Cancers

G. Prendergast, M. Kagey, J. Bendell, 2021, Molecular Cancer Therapeutics.

A Phase 1b Trial of Prexasertib in Combination with Standard-of-Care Agents in Advanced or Metastatic Cancer

Suzanne F. Jones, F. Meric-Bernstam, J. Bendell, 2021, Targeted Oncology.

Phase III Study to Evaluate Efficacy and Safety of Andecaliximab With mFOLFOX6 as First-Line Treatment in Patients With Advanced Gastric or GEJ Adenocarcinoma (GAMMA-1)

J. Ajani, M. Shah, G. Bodoky, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Preclinical Evaluation and Phase Ib Study of Prexasertib, a CHK1 Inhibitor, and Samotolisib (LY3023414), a Dual PI3K/mTOR Inhibitor

Suzanne F. Jones, J. Bendell, D. Hong, 2021, Clinical Cancer Research.

First-in-human, dose-escalation, phase 1 study of anti-angiopoietin-2 LY3127804 as monotherapy and in combination with ramucirumab in patients with advanced solid tumours

J. Bendell, A. Hollebecque, P. Aftimos, 2020, British Journal of Cancer.

First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody–Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors

J. Nemunaitis, J. Bendell, B. Childs, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE).

J. Bendell, A. Ko, F. Rivera, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase 2 study of an oral mTORC1/mTORC2 kinase inhibitor (CC-223) for non-pancreatic neuroendocrine tumors with or without carcinoid symptoms

J. Nemunaitis, T. Meyer, L. Paz-Ares, 2019, PloS one.

Regorafenib Prior to Selective Internal Radiation Therapy Using 90Y-Resin Microspheres for Refractory Metastatic Colorectal Cancer Liver Metastases: Analysis of Safety, Dosimetry, and Molecular Markers

J. Bendell, A. McKenzie, Maxim Shpak, 2019, Front. Oncol..

A Phase Ib/II Study of Ramucirumab in Combination with Emibetuzumab in Patients with Advanced Cancer

A. Drilon, T. Choueiri, M. Voss, 2019, Clinical Cancer Research.

A phase I study of ABT-510 plus bevacizumab in advanced solid tumors

H. Hurwitz, J. Bendell, G. Blobe, 2013, Cancer medicine.

A phase I, open-label, multicenter study to assess the safety, pharmacokinetics, and preliminary antitumor activity of AZD4635 both as monotherapy and in combination in patients with advanced solid malignancies: Results from prostate cancer patients (NCT02740985).

B. Linghu, C. Drake, J. Bendell, 2020 .

Immunologic and tumor responses of pegilodecakin with 5-FU/LV and oxaliplatin (FOLFOX) in pancreatic ductal adenocarcinoma (PDAC)

J. Hecht, Z. Wainberg, K. Papadopoulos, 2020, Investigational New Drugs.

A phase 1b study of trametinib, an oral Mitogen-activated protein kinase kinase (MEK) inhibitor, in combination with gemcitabine in advanced solid tumours.

Suzanne F. Jones, A. Tolcher, N. Le, 2013, European journal of cancer.

513O A phase I/II multicenter, first-in-human study of DS-7300 (B7-H3 DXd-ADC) in patients (pts) with advanced solid tumors

Toshio Shimizu, Melissa L. Johnson, M. R. Patel, 2021, Annals of Oncology.

Phase I Escalation and Expansion Study of Bemarituzumab (FPA144) in Patients With Advanced Solid Tumors and FGFR2b-Selected Gastroesophageal Adenocarcinoma

Y. Bang, P. Enzinger, Z. Wainberg, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study

A. Gasbarrini, M. Kudo, J. Bruix, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

“ PERSONALIZED ” ONCOLOGY FOR COLORECTAL CANCER : READY FOR PRIME TIME OR STOP THE TRAIN ?

A. Venook, J. Bendell, R. Warren, 2012 .

1030P First-in-human study of camidanlumab tesirine (ADCT-301, Cami), an anti-CD25 targeted therapy in patients (pts) with advanced solid tumours: Pharmacokinetics (PK) and biomarker evaluation

I. Puzanov, J. Bendell, J. Wuerthner, 2020 .

Phase 1, Open-Label, Dose Escalation, Safety, and Pharmacokinetics Study of ME-344 as a Single Agent in Patients With Refractory Solid Tumors

Suzanne F. Jones, J. Bendell, H. Burris, 2014, Cancer.

Development and Preliminary Clinical Activity of PD-1-Guided CTLA-4 Blocking Bispecific DART Molecule

P. Moore, J. Bendell, J. Luke, 2020, Cell reports. Medicine.

Phase I Study of LY2940680, a Smo Antagonist, in Patients with Advanced Cancer Including Treatment-Naïve and Previously Treated Basal Cell Carcinoma

D. V. Von Hoff, A. Ho, J. Bendell, 2018, Clinical Cancer Research.

KEYNOTE-177: Phase 3, open-label, randomized study of first-line pembrolizumab (Pembro) versus investigator-choice chemotherapy for mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal carcinoma (mCRC).

D. Jäger, L. Diaz, J. Bendell, 2018 .

A phase I study of MEK inhibitor MEK162 (ARRY-438162) in patients with biliary tract cancer.

R. Finn, T. Bekaii-Saab, A. Patnaik, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

CX-072 (pacmilimab), a Probody® PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): an open-label dose-finding and first-in-human study

P. LoRusso, P. Ott, J. Bendell, 2021, Journal for ImmunoTherapy of Cancer.

A Phase 1a/b Open‑Label, Dose‑Escalation Study of Etigilimab Alone or in Combination with Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumors.

J. Bendell, J. Strickler, L. Faoro, 2021, Clinical cancer research : an official journal of the American Association for Cancer Research.

ClarIDHy: A phase 3, multicenter, randomized, double-blind study of AG-120 vs placebo in patients with an advanced cholangiocarcinoma with an IDH1 mutation.

A. Zhu, M. Borad, G. Abou-Alfa, 2017 .

Safety and efficacy of nivolumab plus ipilimumab in patients with advanced renal cell carcinoma with brain metastases: CheckMate 920

J. Bendell, D. Cho, D. George, 2021, Cancer.

DKN-01 in combination with pembrolizumab in patients with advanced gastroesophageal adenocarcinoma (GEA): Tumoral DKK1 expression as a predictor of response and survival.

M. Kagey, J. Bendell, V. Villaflor, 2020 .

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, Brian D. Kelly, 2016, Journal of Immunotherapy for Cancer.

A phase IB trial of the oral MEK inhibitor trametinib (GSK1120212) in combination with everolimus in patients with advanced solid tumors.

A. Tolcher, N. Le, D. Rasco, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Safety analysis of a randomized phase II trial of hedgehog pathway inhibitor (HPI) GDC-0449 versus placebo with FOLFOX or FOLFIRI and bevacizumab in patients with previously untreated metastatic colorectal cancer (mCRC).

J. Berlin, L. Hart, R. Hermann, 2010 .

Bevacizumab, oxaliplatin, and capecitabine with radiation therapy in rectal cancer: Phase I trial results.

John Thomas, Daohai Yu, C. Willett, 2007, International journal of radiation oncology, biology, physics.

Effect of Celecoxib vs Placebo Added to Standard Adjuvant Therapy on Disease-Free Survival Among Patients With Stage III Colon Cancer: The CALGB/SWOG 80702 (Alliance) Randomized Clinical Trial.

J. Meyerhardt, M. Bertagnolli, C. Fuchs, 2021, JAMA.

A first-in-human dose-escalation study of ME-143, a second generation NADH oxidase inhibitor, in patients with advanced solid tumors

Suzanne F. Jones, J. Bendell, H. Burris, 2013, Investigational New Drugs.

ME-143, a novel inhibitor of tumor-specific NADH oxidase (tNOX): Results from a first-in-human phase I study.

Suzanne F. Jones, J. Bendell, H. Burris, 2012 .

Phase Ib study of dulanermin combined with FOLFIRI (with or without bevacizumab [BV]) in previously treated patients (Pts) with metastatic colorectal cancer (mCRC).

J. Bendell, A. Ashkenazi, M. Kozloff, 2012 .

A phase Ib/II study of the anti-CD47 antibody magrolimab with cetuximab in solid tumor and colorectal cancer patients.

J. Hecht, P. Philip, C. Takimoto, 2020 .

Disease Monitoring Using Post-induction Circulating Tumor DNA Analysis Following First-Line Therapy in Patients with Metastatic Colorectal Cancer

H. Hurwitz, S. Yaung, J. Bendell, 2020, Clinical Cancer Research.

A phase I dose escalation study of oral c-MET inhibitor tivantinib (ARQ 197) in combination with gemcitabine in patients with solid tumors.

Suzanne F. Jones, Yulei N. Wang, J. Bendell, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

A first-in-human dose-escalation study of the oral proteasome inhibitor oprozomib in patients with advanced solid tumors

A. Tolcher, K. Papadopoulos, J. Bendell, 2016, Investigational New Drugs.

Neoadjuvant Treatment for Resectable and Locally Advanced Pancreatic Cancer

R. Petersen, D. Tyler, J. Bendell, 2008 .

Checkmate 032: Nivolumab (N) alone or in combination with ipilimumab (I) for the treatment of recurrent small cell lung cancer (SCLC).

D. Jäger, P. Ascierto, P. Ott, 2016 .

Durvalumab + monalizumab, mFOLFOX6, and bevacizumab in patients (pts) with metastatic microsatellite-stable colorectal cancer (MSS-CRC)

J. Bendell, B. Carneiro, J. Naidoo, 2019, Annals of Oncology.

Phase 1b investigation of the MEK inhibitor binimetinib in patients with advanced or metastatic biliary tract cancer

M. Sawyer, R. Finn, T. Bekaii-Saab, 2018, Investigational New Drugs.

A phase II trial of bevacizumab plus everolimus for patients with refractory metastatic colorectal cancer.

H. Hurwitz, J. Bendell, G. Blobe, 2011, The oncologist.

A phase I, dose-escalation study of pomalidomide (CC-4047) in combination with gemcitabine in metastatic pancreas cancer.

Suzanne F. Jones, J. Hainsworth, J. Bendell, 2011, European journal of cancer.

Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of Dalantercept, an Activin Receptor–like Kinase-1 Ligand Trap, in Patients with Advanced Cancer

Suzanne F. Jones, N. Agarwal, H. Hurwitz, 2013, Clinical Cancer Research.

A Phase II Study of the c-Met Inhibitor Tivantinib in Combination with FOLFOX for the Treatment of Patients with Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction, or Stomach

J. Bendell, C. Kurkjian, S. Pant, 2017, Cancer investigation.

Combining tumor deposits with the number of lymph node metastases to improve the prognostic accuracy in stage III colon cancer: a post hoc analysis of the CALGB/SWOG 80702 phase III study (Alliance).

M. Bertagnolli, A. Shields, J. Bendell, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase I study of the oral mTOR inhibitor ridaforolimus (RIDA) in combination with the IGF-1R antibody dalotozumab (DALO) in patients (pts) with advanced solid tumors.

J. Baselga, S. Cosimo, J. Bendell, 2010 .

Targeted agents in the treatment of pancreatic cancer: history and lessons learned

R. Goldberg, J. Bendell, 2007, Current opinion in oncology.

Lenalidomide in combination with gemcitabine as first-line treatment for patients with metastatic carcinoma of the pancreas: A Sarah Cannon Research Institute phase II trial

J. Hainsworth, J. Bendell, J. Infante, 2013, Cancer biology & therapy.

Final overall survival for the phase III KN177 study: Pembrolizumab versus chemotherapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC).

P. Gibbs, C. Punt, Tae Won Kim, 2021 .

First in human phase I/IIa study of PEN-866, a heat shock protein 90 (HSP90) ligand – SN38 conjugate for patients with advanced solid tumours: Phase I results

Melissa L. Johnson, J. Bendell, G. Falchook, 2019, Annals of Oncology.

Phase I study of ACE-041, a novel inhibitor of ALK1-mediated angiogenesis, in patients with advanced solid tumors.

H. Hurwitz, J. Bendell, M. Gordon, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Combination of themTOR Inhibitor Ridaforolimus and the Anti-IGF1R Monoclonal Antibody Dalotuzumab: Preclinical Characterization and Phase I Clinical Trial

S. Cosimo, J. Bendell, B. Haines, 2014 .

Clinical combination of the MEK inhibitor GDC-0973 and the PI3K inhibitor GDC-0941: A first-in-human phase Ib study testing daily and intermittent dosing schedules in patients with advanced solid tumors.

C. Jones, A. D. de Crespigny, M. Belvin, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abstract LB041: THOR-707 (SAR444245), a novel not-alpha IL-2 as monotherapy and in combination with pembrolizumab in advanced/metastatic solid tumors: Interim results from HAMMER, an open-label, multicenter phase 1/2 Study

F. Janku, J. Bendell, M. Milla, 2021, Clinical Research (Excluding Clinical Trials).

P-325 Oral delivery of a single microbial strain, EDP1503, induces anti-tumor responses via gut-mediated activation of both innate and adaptive immunity

P. Sandy, J. Bendell, M. Bodmer, 2020 .

Ramucirumab in Combination with Pembrolizumab in Treatment-Naïve Advanced Gastric or GEJ Adenocarcinoma: Safety and Antitumor Activity from the Phase 1a/b JVDF Trial

L. Zender, R. Herbst, C. Fuchs, 2020, Cancers.

A phase 1 study of ramucirumab (R) plus pembrolizumab (P) in patients (pts) with advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, non-small cell lung cancer (NSCLC), or urothelial carcinoma (UC): Phase 1a results.

R. Herbst, J. Bendell, D. Ferry, 2016 .

Safety and efficacy of MPDL3280A (anti-PDL1) in combination with bevacizumab (bev) and/or FOLFOX in patients (pts) with metastatic colorectal cancer (mCRC).

H. Hurwitz, J. Bendell, M. Pishvaian, 2015 .

Phase II study of bevacizumab and chemoradiation in the preoperative or adjuvant treatment of patients with stage II/III rectal cancer.

J. Hainsworth, J. Bendell, H. Burris, 2012, Clinical colorectal cancer.

Phase 1 study of glutaminase (GLS) inhibitor CB-839 combined with either everolimus (E) or cabozantinib (Cabo) in patients (pts) with clear cell (cc) and papillary (pap) metastatic renal cell cancer (mRCC).

R. Srinivasan, M. Voss, G. Shapiro, 2018 .

Phase I Study of CC-486 Alone and in Combination with Carboplatin or nab-Paclitaxel in Patients with Relapsed or Refractory Solid Tumors

J. Schellens, E. Heath, P. LoRusso, 2018, Clinical Cancer Research.

Randomized Phase III Study of FOLFOX Alone and with Pegilodecakin as Second-line Therapy in Patients with Metastatic Pancreatic Cancer (SEQUOIA).

Joon-Oh Park, R. Greil, J. Hecht, 2020 .

Duodenal adenocarcinoma: patterns of failure after resection and the role of chemoradiotherapy.

C. Willett, R. Clough, H. Hurwitz, 2007, International journal of radiation oncology, biology, physics.

Telaglenastat Plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase 2 ENTRATA Trial.

R. Motzer, J. Hsieh, Chung-Han Lee, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Telaglenastat Plus Cabozantinib or Everolimus For Advanced or Metastatic Renal Cell Carcinoma: an Open-Label Phase 1 Trial.

R. Srinivasan, M. Voss, A. DeMichele, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

A Phase I/biomarker study of bevacizumab in combination with CNTO 95 in patients with advanced solid tumors

H. Hurwitz, J. Bendell, H. Pang, 2015, Cancer Chemotherapy and Pharmacology.

Phase 1/2 study of KRN330, a fully human anti-A33 monoclonal antibody, plus irinotecan as second-line treatment for patients with metastatic colorectal cancer

J. Berlin, T. Ryan, H. Lenz, 2014, Investigational New Drugs.

Final results of a randomized phase II study of perifosine in combination with capecitabine (P-CAP) versus placebo plus capecitabine (CAP) in patients (pts) with second- or third-line metastatic colorectal cancer (mCRC).

J. Nemunaitis, R. Hermann, J. Bendell, 2010 .

Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumors

Suzanne F. Jones, C. Rudin, G. Shapiro, 2019, Investigational New Drugs.

495 Trial of SNX281, a systemically delivered small molecule STING agonist, in solid tumors and lymphomas

P. Sandy, J. Bendell, Meghana Kulkarni, 2021, Journal for ImmunoTherapy of Cancer.

Phase II Randomized Trial of Sequential or Concurrent FOLFOXIRI-Bevacizumab Versus FOLFOX-Bevacizumab for Metastatic Colorectal Cancer (STEAM).

J. Reeves, B. Somer, H. Lenz, 2019, The oncologist.

Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer

J. Bendell, J. Infante, R. Mayer, 2015, Cancer Chemotherapy and Pharmacology.

2136 : Adenocarcinoma of the Duodenum: A 30-Year Experience

C. Willett, H. Hurwitz, D. Tyler, 2006 .

A Randomized Phase II Open-Label Multi-Institution Study of the Combination of Bevacizumab and Erlotinib Compared to Sorafenib in the First-Line Treatment of Patients with Advanced Hepatocellular Carcinoma

G. Weiss, M. Thomas, A. El-Khoueiry, 2018, Oncology.

Phase 1b/2 study of enzalutamide (ENZ) with LY3023414 (LY) or placebo (PL) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) after progression on abiraterone.

J. Bendell, D. Morris, C. Albany, 2019, Journal of Clinical Oncology.

Interim safety and clinical activity in patients with advanced NSCLC from a multi-cohort phase 1 study of ramucirumab (R) plus pembrolizumab (P)

R. Herbst, L. Paz-Ares, J. Bendell, 2016 .

Analyses of PD-L1 and Inflammatory Gene Expression Association with Efficacy of Nivolumab ± Ipilimumab in Gastric Cancer/Gastroesophageal Junction Cancer

P. Sharma, F. D. De Braud, Han Chang, 2021, Clinical Cancer Research.

Phase I, open-label, dose-escalation study of AZD7762 in combination with irinotecan (irino) in patients (pts) with advanced solid tumors.

G. Shapiro, G. Schwartz, A. Ho, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bevacizumab (BV) plus chemotherapy (CT) in second-line metastatic colorectal cancer (mCRC): Initial results from ARIES, a second BV observational cohort study (OCS).

A. Grothey, H. Hurwitz, T. Bekaii-Saab, 2010 .

Abstract A120: A Phase Ib study of CC-486 (Oral Azacitidine) as a priming agent for carboplatin or NAB-paclitaxel in subjects with relapsed and refractory solid tumors.

P. LoRusso, G. Weiss, D. Rasco, 2013 .

Phase I study of the selective BRAFV600inhibitor encorafenib (LGX818) combined with cetuximab and with or without the {alpha}-specific PI3K inhibitor BYL719 in patients with advanced BRAF-mutant colorectal cancer.

R. Bernards, J. Schellens, J. Tabernero, 2014 .

A phase 2 trial of trifluridine/tipiracil plus nivolumab in patients with heavily pretreated microsatellite‐stable metastatic colorectal cancer

J. Bendell, G. Falchook, Kensuke Hamada, 2021, Cancer medicine.

Celecoxib in addition to standard adjuvant therapy with 5-fluorouracil, leucovorin, oxaliplatin (FOLFOX) in stage III colon cancer: Results from CALGB/SWOG 80702.

J. Meyerhardt, M. Bertagnolli, C. Fuchs, 2020 .

A drug interaction study evaluating the pharmacokinetics and toxicity of sorafenib in combination with capecitabine

Suzanne F. Jones, J. Hainsworth, J. Bendell, 2011, Cancer Chemotherapy and Pharmacology.

Multiagent Chemotherapy for Isolated Colorectal Liver Metastases: A Single-centered Retrospective Study

H. Hurwitz, J. Bendell, D. Niedzwiecki, 2008, Journal of Gastrointestinal Surgery.

Phase 1/2 study of durvalumab and tremelimumab as monotherapy and in combination in patients with unresectable hepatocellular carcinoma (HCC).

M. Kudo, A. Zhu, G. Abou-Alfa, 2016 .

A phase II study of the c-Met inhibitor tivantinib (tiv) in combination with FOLFOX for the treatment of patients (pts) with previously untreated metastatic adenocarcinoma of the distal esophagus, gastroesophageal (GE) junction, or stomach.

J. Bendell, C. Kurkjian, S. Pant, 2015 .

Phase I study of GS-5745 alone and in combination with chemotherapy in patients with advanced solid tumors.

M. Shah, Z. Wainberg, J. Bendell, 2015 .

674PNivolumab (NIVO) in patients (pts) with advanced (adv) chemotherapy-refractory (CT-Rx) esophagogastric (EG) cancer according to microsatellite instability (MSI) status: checkmate 032

D. Jäger, P. Ascierto, P. Sharma, 2017 .

Nivolumab ± ipilimumab in pts with advanced (adv)/metastatic chemotherapy-refractory (CTx-R) gastric (G), esophageal (E), or gastroesophageal junction (GEJ) cancer: CheckMate 032 study.

P. Ascierto, P. Sharma, P. Ott, 2017 .

Safety and efficacy of a DKK1 inhibitor (DKN-01) in combination with pembrolizumab (P) in patients (Pts) with advanced gastroesophageal (GE) malignancies.

M. Kagey, J. Bendell, W. Newman, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Abstract CT018: Interim safety and clinical activity in patients (pts) with advanced refractory solid tumors from a phase Ia/b study investigating the novel anti-PD-L1 antibody (LY3300054) administered alone or in combination with other agents

Y. Bang, A. Patnaik, J. Bendell, 2018, Clinical Trials.

Activity of ramucirumab (R) with pembrolizumab (P) by PD-L1 expression in advanced solid tumors: Phase 1a/b study in later lines of therapy.

R. Herbst, C. Fuchs, L. Paz-Ares, 2018 .

A Phase II, Randomized, Double‐Blind, Placebo‐Controlled Study of Simtuzumab in Combination with FOLFIRI for the Second‐Line Treatment of Metastatic KRAS Mutant Colorectal Adenocarcinoma

A. Benson, J. Hecht, J. Bendell, 2017, The oncologist.

Combination of a MEK inhibitor, pimasertib (MSC1936369B), and a PI3K/mTOR inhibitor, SAR245409, in patients with advanced solid tumors: Results of a phase Ib dose-escalation trial.

J. Baselga, R. Heist, G. Shapiro, 2013 .

Effect of post-discontinuation therapy (PDT) on survival in metastatic gastric-gastroesophageal junction (G-GEJ) adenocarcinoma patients from the RAINFALL trial: An exploratory analysis.

J. Lacy, M. Shah, C. Fuchs, 2018 .

PD-016Current results of a phase I study of DKN-01 in combination with paclitaxel (P) in patients (pts) with advanced DKK1+ esophageal cancer (EC) or gastro-esophageal junction tumors (GEJ)

D. Ryan, J. Bendell, D. Mahalingam, 2016 .

Phase 1 dose escalation of XMT-1522, a novel HER2-targeting antibody-drug conjugate (ADC), in patients (pts) with HER2-expressing breast, lung and gastric tumors.

D. Bergstrom, A. Bardia, M. Beeram, 2018 .

Phase 1b/2 study of binimetinib (BINI) in combination with nivolumab (NIVO) or NIVO plus ipilimumab (IPI) in patients (pts) with previously treated microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) with RAS mutation.

S. Kopetz, J. Bendell, M. Middleton, 2018 .

Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of TH-302, a Hypoxia-Activated Prodrug, in Patients with Advanced Solid Malignancies

Suzanne F. Jones, M. Lacouture, M. Borad, 2011, Clinical Cancer Research.

GB1275, a first-in-class CD11b modulator: rationale for immunotherapeutic combinations in solid tumors

J. Bendell, J. Dupont, Lei Zhou, 2021, Journal for ImmunoTherapy of Cancer.

A phase Ib study of linsitinib (OSI-906), a dual inhibitor of IGF-1R and IR tyrosine kinase, in combination with everolimus as treatment for patients with refractory metastatic colorectal cancer

Suzanne F. Jones, L. Hart, J. Bendell, 2015, Investigational New Drugs.

Radiation Therapy in Stage II and III Rectal Cancer

C. Willett, J. Bendell, B. Czito, 2007, Clinical Cancer Research.

CB-839, a glutaminase inhibitor, in combination with cabozantinib in patients with clear cell and papillary metastatic renal cell cancer (mRCC): Results of a phase I study.

R. Srinivasan, M. Voss, G. Shapiro, 2019, Journal of Clinical Oncology.

A phase II study of capecitabine, oxaliplatin, bevacizumab and cetuximab in the treatment of metastatic colorectal cancer.

H. Hurwitz, J. Bendell, G. Blobe, 2011, Anticancer research.

Bevacizumab (B) plus everolimus (E) and panitumumab (P) in refractory advanced solid tumors.

H. Hurwitz, R. Riedel, J. Bendell, 2016, Journal of Clinical Oncology.

NRG Oncology Radiation Therapy Oncology Group 0822: A Phase 2 Study of Preoperative Chemoradiation Therapy Using Intensity Modulated Radiation Therapy in Combination With Capecitabine and Oxaliplatin for Patients With Locally Advanced Rectal Cancer.

J. Bendell, T. Hong, S. Jabbour, 2015, International journal of radiation oncology, biology, physics.

Abstract LB-89: Clinical combination of the MEK inhibitor GDC-0973 and the PI3K inhibitor GDC-0941: A first-in-human phase Ib study in patients with advanced solid tumors

M. Belvin, G. Shapiro, P. LoRusso, 2011 .

A phase III, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of andecaliximab combined with mFOLFOX6 as first-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma (GAMMA-1).

J. Ajani, M. Shah, G. Bodoky, 2019, Journal of Clinical Oncology.

Andecaliximab/GS-5745 Alone and Combined with mFOLFOX6 in Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Results from a Phase I Study

J. Berlin, M. Shah, H. Lenz, 2018, Clinical Cancer Research.

LBA-003Phase 1b/II study of cancer stemness inhibitor napabucasin in combination with FOLFIRI +/- bevacizumab (bev) in metastatic colorectal cancer (mCRC) patients (pts).

A. Grothey, J. Bendell, H. Pitot, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

FOLFOXIRI-bevacizumab or FOLFOX-panitumumab in left-sided RAS/BRAF wild-type metastatic colorectal cancer patients: a propensity score-based analysis.

L. Boni, J. Bendell, D. Rossini, 2020, The oncologist.

P-71 KRYSTAL-10: A randomized phase 3 study of adagrasib (MRTX849) in combination with cetuximab vs chemotherapy in patients with previously treated advanced colorectal cancer with KRASG12C mutation

J. Tabernero, R. Yaeger, S. Kopetz, 2021, Annals of Oncology.

Nivolumab monotherapy in patients with advanced gastric or gastroesophageal junction (GEJ) cancer and 2 or more prior treatment regimens: Sub-analysis of the CheckMate 032 study.

P. Ascierto, P. Sharma, P. Ott, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

A. Grothey, H. Hurwitz, T. Bekaii-Saab, 2011, Journal of Clinical Oncology.

Effectiveness of first- or second-line bevacizumab (BV) treatment (tx) in elderly patients (pts) with metastatic colorectal cancer (mCRC) in ARIES, an observational cohort study (OCS).

A. Grothey, H. Hurwitz, T. Bekaii-Saab, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

618PDA PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY OF SIMTUZUMAB OR PLACEBO IN COMBINATION WITH GEMCITABINE FOR THE FIRST LINE TREATMENT OF PANCREATIC ADENOCARCINOMA.

A. Benson, Z. Wainberg, J. Bendell, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I dose-escalation studies of SNX-5422, an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumours.

Suzanne F. Jones, D. V. Von Hoff, G. Weiss, 2014, European journal of cancer.

Phase I/II study of neoadjuvant bevacizumab with radiation therapy and 5-fluorouracil in patients with rectal cancer: initial results

R. Jain, Y. Boucher, C. Willett, 2007 .

Single agent HuMab-5B1 (MVT-5873), a monoclonal antibody targeting sLea, in patients with pancreatic cancer and other CA19-9 positive malignancies.

M. Lowery, A. Varghese, P. Klein, 2017 .

The McCAVE Trial: Vanucizumab plus mFOLFOX‐6 Versus Bevacizumab plus mFOLFOX‐6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC)

H. Hurwitz, J. Bendell, K. Lechner, 2019, The oncologist.

Correlation of GPNMB expression with outcome in breast cancer (BC) patients treated with the antibody–drug conjugate (ADC), CDX-011 (CR011-vcMMAE).

Suzanne F. Jones, L. Hart, J. Bendell, 2010 .

O82 A phase 1 dose escalation study of PRS-343, a HER2/4–1BB bispecific molecule, in patients with HER2-positive malignancies

A. Tolcher, L. Matis, I. Bruns, 2020, Journal of Immunotherapy for Cancer.

CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): a first-in-human, dose-finding study

R. Plummer, E. D. de Vries, P. Ott, 2021, Journal for ImmunoTherapy of Cancer.

Nivolumab monotherapy in metastatic urothelial carcinoma: Longer-term efficacy and safety results from the CheckMate 032 study.

D. Jäger, P. Sharma, P. Ott, 2018 .

A Phase I Study of the Hsp90 Inhibitor AUY922 plus Capecitabine for the Treatment of Patients with Advanced Solid Tumors

Suzanne F. Jones, L. Hart, J. Bendell, 2015, Cancer investigation.

Abstract C127: Factors affecting the pharmacokinetics (PK) and pharmacodynamics (PD) of PEGylated liposomal irinotecan (IHL‐305) in patients with advanced solid tumors

Suzanne F. Jones, E. Chan, J. Bendell, 2009 .

Safety and efficacy of nivolumab plus ipilimumab (NIVO+IPI) in patients with advanced renal cell carcinoma (aRCC) with brain metastases: Interim analysis of CheckMate 920.

J. Bendell, D. Cho, D. George, 2019, Journal of Clinical Oncology.

ARC-6: A phase 1b/2, open-label, randomized platform study to evaluate efficacy and safety of etrumadenant (AB928)-based treatment combinations in patients with metastatic castrate-resistant prostate cancer (mCRPC).

M. Carducci, J. Bendell, O. Gardner, 2021 .

ARC-9: Phase Ib/II study to evaluate etrumadenant (AB928)-based treatment combinations in patients with metastatic colorectal cancer (mCRC).

J. Bendell, N. Giafis, C. Quah, 2021 .

A phase Ia study of CC-90003, a selective extracellular signal regulated kinase (ERK) inhibitor, in patients with relapsed or refractory BRAF or RAS-mutant tumors.

Edward S. Kim, P. LoRusso, J. Bendell, 2017 .

A Phase I Study of an IDO-1 Inhibitor (LY3381916) as Monotherapy and in Combination With an Anti-PD-L1 Antibody (LY3300054) in Patients With Advanced Cancer

T. Doman, Abhijoy Saha, S. Jalal, 2021, Journal of immunotherapy.

Overall response rate (ORR) in STEAM, a randomized, open-label, phase 2 trial of sequential and concurrent FOLFOXIRI-bevacizumab (BEV) vs FOLFOX-BEV for the first-line (1L) treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC).

J. Reeves, B. Somer, H. Lenz, 2016 .

A phase I dose-escalation study of IMGN388 in patients with solid tumors.

A. Tolcher, A. Patnaik, J. Bendell, 2010 .

1386P Phase II study of bavituximab (bavi), a first-in-class antibody targeting phosphatidylserine (PS), plus pembrolizumab (pembro) in advanced gastric or gastroesophageal junction (GEJ) cancer

J. Bendell, H. Youssoufian, I. Chau, 2021, Annals of Oncology.

A phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of GS-5745 combined with mFOLFOX6 as first-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma.

M. Shah, Z. Wainberg, J. Bendell, 2017 .

Intermittent dosing of RMC-4630, a potent, selective inhibitor of SHP2, combined with the MEK inhibitor cobimetinib, in a phase 1b/2 clinical trial for advanced solid tumors with activating mutations of RAS signaling

J. Riess, S. Ou, J. Bendell, 2020, European Journal of Cancer.

A phase I dose escalation (DE) study of ERK inhibitor, LY3214996, in advanced (adv) cancer (CA) patients (pts).

R. Sullivan, G. Shapiro, J. Bendell, 2019, Journal of Clinical Oncology.

Costs Associated with Capecitabine or 5-Fluorouracil Monotherapy after Surgical Resection in Patients with Colorectal Cancer

J. Bendell, E. Chu, T. Cartwright, 2009, Oncology.

Efficacy and safety results from IMblaze370, a randomised Phase III study comparing atezolizumab+cobimetinib and atezolizumab monotherapy vs regorafenib in chemotherapy-refractory metastatic colorectal cancer.

J. Tabernero, N. Segal, M. Fakih, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase I, open-label, dose-escalation study of the novel oral proteasome inhibitor (PI) ONX 0912 in patients with advanced refractory or recurrent solid tumors.

A. Tolcher, K. Papadopoulos, D. Rasco, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase II Study of the Combination of Bevacizumab, Pertuzumab, and Octreotide LAR for Patients with Advanced Neuroendocrine Cancers

J. Bendell, N. Peacock, D. Waterhouse, 2016, Cancer investigation.

Efficacy and safety of cobimetinib (cobi) and atezolizumab (atezo) in an expanded phase 1b study of microsatellite-stable (MSS) metastatic colorectal cancer (mCRC)

J. Desai, Y. Bang, E. Kwak, 2016 .

Phase I study of safety and pharmacokinetics (PK) of GDC-0917, an antagonist of inhibitor of apoptosis (IAP) proteins in patients (Pts) with refractory solid tumors or lymphoma.

A. Tolcher, F. Peale, K. Papadopoulos, 2013 .

A randomized, double-blind, phase II study of first-line FOLFOX plus bevacizumab with onartuzumab versus placebo in patients with metastatic colorectal cancer (mCRC).

L. Hart, J. Bendell, D. Shames, 2015 .

Abstract B75: A first in-human phase I study to evaluate the MEK1/2 inhibitor GDC-0623 in patients with advanced solid tumors.

A. El-Khoueiry, J. Bendell, I. Chang, 2013 .

Therapeutic targeting of SLC6A8 creatine transporter suppresses colon cancer progression and modulates human creatine levels

S. Tavazoie, Shugaku Takeda, K. Manova-Todorova, 2021, Science advances.

Abstract CT328: Clinical results of a phase Ib dose-escalation study of the Mek inhibitor cobimetinib (GDC-0973) and the Akt inhibitor ipatasertib (GDC-0068) in patients (pts) with solid tumors

G. Shapiro, P. LoRusso, J. Bendell, 2014 .

Abstract LB-147: Combination of the MEK inhibitor, pimasertib (MSC1936369B), and the PI3K/mTOR inhibitor, SAR245409, in patients with advanced solid tumors: Results of a phase Ib dose-escalation trial.

J. Baselga, R. Heist, G. Shapiro, 2013 .

Abstract B128: A phase IB study of the MEK inhibitor GSK1120212 combined with everolimus in patients with solid tumors: Interim results.

Suzanne F. Jones, A. Tolcher, N. Le, 2011 .

Randomized multicenter phase II trial comparing two schedules of etirinotecan pegol (NKTR-102) in women with recurrent platinum-resistant/refractory epithelial ovarian cancer.

G. Rustin, I. Vergote, L. Dirix, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I, first-in-human trial of an oral VEGFR tyrosine kinase inhibitor (TKI) x-82 in patients (pts) with advanced solid tumors.

Suzanne F. Jones, C. Liang, J. Bendell, 2012 .

A randomized double-blind phase 2 study of ruxolitinib (RUX) or placebo (PBO) with capecitabine (CAPE) as second-line therapy in patients (pts) with metastatic pancreatic cancer (mPC).

Nikhil Uppal, Jason Clark, Philip J. Stella, 2014 .

A phase IB trial of the oral MEK inhibitor trametinib (GSK1120212) in combination with everolimus in patients with advanced solid tumors.

A. Tolcher, N. Le, D. Rasco, 2015 .

CARRIE: A randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer.

J. Bendell, A. Ko, D. Watkins, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

First-in-human study of the anti-HB-EGF antibody U3-1565 in subjects with advanced solid tumors

P. LoRusso, J. Bendell, G. Senaldi, 2018, Investigational New Drugs.

First-in-human study of oleclumab, a potent, selective anti-CD73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumors

J. Desai, Dong-Wan Kim, J. Bendell, 2023, Cancer Immunology, Immunotherapy.

Predictive potential of angiopoietin-2 in a mCRC subpopulation treated with vanucizumab in the McCAVE trial

I. Klaman, J. Bendell, K. Lechner, 2023, Frontiers in Oncology.

A randomized phase II study of cabiralizumab (cabira) + nivolumab (nivo) ± chemotherapy (chemo) in advanced pancreatic ductal adenocarcinoma (PDAC).

T. Seufferlein, Z. Wainberg, J. Bendell, 2019, Journal of Clinical Oncology.

Overall survival of PEGylated human IL-10 (AM0010) with 5-FU/LV and oxaliplatin (FOLFOX) in metastatic pancreatic adenocarcinoma (PDAC).

J. Hecht, Z. Wainberg, K. Papadopoulos, 2018 .

Phase I/II sequencing study of azacitidine, epacadostat, and pembrolizumab in advanced solid tumors

R. Kurzrock, M. Fakih, J. Bendell, 2023, British Journal of Cancer.

Updated efficacy of the MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E mutated (BRAFm) metastatic colorectal cancer (mCRC).

C. Atreya, J. Schellens, J. Tabernero, 2015 .

Phase II study of NK012 in relapsed small cell lung cancer.

J. Hainsworth, J. Bendell, H. Burris, 2011, Journal of Clinical Oncology.

A phase II, randomized, double-blinded, placebo-controlled study of simtuzumab or placebo in combination with FOLFIRI for the second line treatment of metastatic KRAS mutant colorectal adenocarcinoma.

J. Hecht, J. Bendell, K. Bencardino, 2015 .

Epacadostat Plus Pembrolizumab and Chemotherapy for Advanced Solid Tumors: Results from the Phase I/II ECHO-207/KEYNOTE-723 Study

J. Bendell, A. Naing, D. Catenacci, 2022, The oncologist.

Complete pathological response to bevacizumab and chemoradiation in advanced rectal cancer

R. Jain, Y. Boucher, E. Paulson, 2007, Nature Clinical Practice Oncology.

Abstract CT302: Phase Ia/Ib dose-escalation study of the anti-TIGIT antibody tiragolumab as a single agent and in combination with atezolizumab in patients with advanced solid tumors

J. Desai, Robert W. Hsieh, K. Morrissey, 2020 .

A Phase (Ph) I/II Study of CR011-VcMMAE, an Antibody-Drug Conjugate, in Patients (Pts) with Locally Advanced or Metastatic Breast Cancer (MBC).

L. Hart, J. Bendell, P. Siegel, 2009 .

A phase I dose escalation study of oral c-MET inhibitor tivantinib (ARQ 197) in combination with gemcitabine in patients with solid tumors.

Y. Wang, J. Bendell, L. Camacho, 2014 .

Treatment rationale and study design for a randomized, double-blind, placebo-controlled phase II study evaluating onartuzumab (MetMAb) in combination with bevacizumab plus mFOLFOX-6 in patients with previously untreated metastatic colorectal cancer.

J. Bendell, S. Hack, M. Saleh, 2013, Clinical colorectal cancer.

Consideration of an association between performance status and ramucirumab efficacy.

Z. Wainberg, J. Bendell, H. Yoon, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Results of a randomized phase II trial of an anti-notch 2/3, tarextumab (OMP-59R5, TRXT, anti-Notch2/3), in combination with nab-paclitaxel and gemcitabine (Nab-P+Gem) in patients (pts) with untreated metastatic pancreatic cancer (mPC).

A. Bullock, J. Bendell, J. Dupont, 2017 .

Clinical activity of the oral MEK1/MEK2 inhibitor GSK1120212 in pancreatic and colorectal cancer.

J. Bendell, J. Infante, L. Fecher, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors.

H. Hurwitz, J. Bendell, M. Morse, 2012, Journal of Clinical Oncology.

Phase 1b study of the oral gemcitabine ‘Pro-drug’ LY2334737 in combination with capecitabine in patients with advanced solid tumors

J. Bendell, J. Infante, W. Ma, 2015, Investigational New Drugs.

A phase I study of panobinostat (LBH589) with capecitabine with or without lapatinib.

Suzanne F. Jones, J. Bendell, H. Burris, 2010 .

Impact of race on dose selection of molecular-targeted agents in early-phase oncology trials

Bhavani G. Murugesan, P. LoRusso, G. Schwartz, 2018, British Journal of Cancer.

Phase Ib results of c-MET inhibitor ARQ 197 in combination with gemcitabine in a cohort of patients (pts) with advanced breast, ovarian, and uterine tumors.

J. Bendell, L. Camacho, G. Abbadessa, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors.

J. Desai, B. Goh, Y. Bang, 2019 .

Open-label phase II/III study of nivolumab plus standard of care versus standard of care for first-line treatment of metastatic colorectal cancer: Checkmate-9X8.

H. Lenz, J. Tabernero, J. Bendell, 2019, Journal of Clinical Oncology.

Phase I/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032.

P. Ascierto, P. Ott, M. Pietanza, 2015 .

1049OSAFETY AND EFFICACY OF MPDL3280A (ANTI-PDL1) IN COMBINATION WITH BEVACIZUMAB (BEV) AND/OR CHEMOTHERAPY (CHEMO) IN PATIENTS (PTS) WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS.

H. Hurwitz, J. Bendell, M. Pishvaian, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Safety and antitumor activity from the phase Ib study of ramucirumab plus pembrolizumab in treatment-naïve advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (JVDF).

L. Zender, J. Bendell, D. Ferry, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Abstract LB-291: First-in-human phase I dose escalation study of a novel anti-mesothelin antibody drug conjugate (ADC), BAY 94-9343, in patients with advanced solid tumors.

Suzanne F. Jones, J. Bendell, H. Burris, 2013 .

A phase Ib study of safety and clinical activity of atezolizumab (A) and cobimetinib (C) in patients (pts) with metastatic colorectal cancer (mCRC).

J. Desai, Y. Bang, Tae Won Kim, 2018 .

A phase I open-label trial evaluating the cardiovascular safety of regorafenib in patients with advanced cancer

David C. Smith, Robin L. Jones, J. Bendell, 2015, Cancer Chemotherapy and Pharmacology.

Preliminary results from an open-label, multicenter phase 1/2 dose escalation and expansion study of THOR-707, a novel not-Alpha IL-2, as a single agent in adult subjects with advanced or metastatic solid tumors

F. Janku, J. Bendell, M. Milla, 2020 .

Abstract B137: Pharmacokinetics and pharmacodynamic biomarkers for the dual PI3K/mTOR inhibitor GDC‐0980: Initial phase I evaluation

G. Jayson, J. Ware, J. Soria, 2009 .

Final results of the McCAVE trial: A double-blind, randomized phase 2 study of vanucizumab (VAN) plus FOLFOX vs. bevacizumab (BEV) plus FOLFOX in patients (pts) with previously untreated metastatic colorectal carcinoma (mCRC).

Cristina Santos, H. Hurwitz, J. Bendell, 2017 .

A phase 1 study to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, and antitumor activity of MEDI9447 alone and in combination with durvalumab (MEDI4736) in patients with advanced solid tumors.

J. Bendell, C. Leow, J. Strickler, 2016 .

525O A phase I dose escalation study of PRS-343, a HER2/4-1BB bispecific molecule, in patients with HER2-positive malignancies

A. Tolcher, G. Ku, A. El-Khoueiry, 2020, Annals of Oncology.

Phase 1, open-label, dose-escalation study of M3814 + avelumab ± radiotherapy (RT) in patients (pts) with advanced solid tumors.

J. Bendell, S. Antonia, F. Beier, 2019, Journal of Clinical Oncology.

Ramucirumab (R) plus pembrolizumab (P) in treatment naive and previously treated advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: A multi-disease phase I study.

R. Herbst, C. Fuchs, J. Bendell, 2017 .

A phase III, double-blind, randomized study of pamiparib versus placebo as maintenance therapy in patients with inoperable, locally advanced, or metastatic gastric cancer (GC) that responded to platinum-based first-line chemotherapy.

Y. Bang, F. Ciardiello, J. Bendell, 2018, Journal of Clinical Oncology.

Circulating copper and zinc levels and risk of hepatobiliary cancers in Europeans

Suzanne F. Jones, A. Tjønneland, K. Overvad, 2017, British Journal of Cancer.

O-7 FOLFIRI ± napabucasin in patients with previously treated metastatic colorectal cancer: Overall survival results from the phase 3 CanStem303C study

M. Shah, J. Tabernero, M. Fakih, 2021, Annals of Oncology.

Evolving Diagnostic and Treatment Strategies for Pancreatic Neuroendocrine Tumors

L. Kvols, J. Bendell, J. Picus, 2011 .

Phase Ib study of the mitochondrial inhibitor ME-344 plus topotecan in patients with previously treated, locally advanced or metastatic small cell lung, ovarian and cervical cancers

H. Gabra, C. Britten, J. Bendell, 2017, Investigational New Drugs.

Impact of race on dose selection of molecular-targeted agents in early-phase oncology trials

Bhavani G. Murugesan, P. LoRusso, G. Schwartz, 2018, British Journal of Cancer.

Phase 1b/2 study of margetuximab (M) plus pembrolizumab (P) in advanced HER2+ gastroesophageal junction (GEJ) or gastric (G) adenocarcinoma (GEA).

S. Park, Y. Bang, Yoon-Koo Kang, 2018 .

A randomized phase 2 study of the Bruton tyrosine kinase (Btk) inhibitor acalabrutinib alone or with pembrolizumab for metastatic pancreatic cancer (mPC).

J. Reeves, P. Philip, J. Nemunaitis, 2016 .

1073TiP A phase I, first-in-human, multicenter, open-label, dose-escalation study of IPH5201 as monotherapy or in combination with durvalumab ± oleclumab in advanced solid tumours

A. Italiano, J. Bendell, B. Carneiro, 2020 .

Phase Ia/b, Open-Label, Multicenter Study of AZD4635 (an Adenosine A2A Receptor Antagonist) as Monotherapy or Combined with Durvalumab, in Patients with Solid Tumors

C. Drake, J. Bendell, D. George, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase I study of PTK787/ZK222584 (PTK/ZK) and RAD001 for patients with advanced solid tumors and dose expansion in renal cell carcinoma patients

A. Armstrong, H. Hurwitz, J. Bendell, 2007 .

Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors

Suzanne F. Jones, J. Bendell, H. Burris, 2015, International journal of nanomedicine.

A phase 3, double-blind, randomized study of pamiparib versus placebo as maintenance therapy in patients with inoperable, locally advanced, or metastatic gastric cancer that responded to platinum-based first-line chemotherapy - Trial in progress.

F. Ciardiello, J. Bendell, M. Raponi, 2018, Annals of Oncology.

Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial.

D. Jäger, P. Ascierto, P. Sharma, 2016, The Lancet. Oncology.

Checkpoint kinase (CHK) 1/2 inhibitor LY2606368 in a phase I, dose-expansion study in patients (pts) with metastatic squamous cell carcinoma (mSCC) of the anus.

Suzanne F. Jones, F. Meric-Bernstam, J. Bendell, 2015 .

Phase 3, open-label, randomized study of first-line pembrolizumab (pembro) vs investigator-choice chemotherapy for mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal carcinoma (mCRC): KEYNOTE-177.

L. Diaz, J. Bendell, D. Jaeger, 2017 .

A Phase-2 Trial of Single Agent Axitinib as Maintenance Therapy Following First-Line Treatment With Modified FOLFOX/Bevacizumab in Patients With Metastatic Colorectal Cancer

J. Bendell, M. Mainwaring, Chris Earwood, 2017, Cancer investigation.

Intermittent dosing of axitinib combined with chemotherapy is supported by 18FLT-PET in gastrointestinal tumours

C. Hoh, J. Bendell, H. Burris, 2014, British Journal of Cancer.

Phase Ib of anticancer stem cell antibody OMP-59R5 (anti-Notch2/3) in combination with nab-paclitaxel and gemcitabine (Nab-P+Gem) in patients (pts) with untreated metastatic pancreatic cancer (mPC).

L. Smith, J. Bendell, J. Dupont, 2014 .

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts

Amanda R. Campbell, F. Lund-Johansen, Yair Benita, 2016 .

Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumors

Suzanne F. Jones, C. Rudin, G. Shapiro, 2019, Investigational new drugs.

Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer.

C. Atreya, R. Kurzrock, D. Ryan, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase II, Randomized, Double‐Blind, Placebo‐Controlled Study of Simtuzumab in Combination with FOLFIRI for the Second‐Line Treatment of Metastatic KRAS Mutant Colorectal Adenocarcinoma

J. Bendell, U. Verma, D. Vyushkov, 2017, The oncologist.

A Phase II Randomized, Double‐Blind, Placebo‐Controlled Study of Simtuzumab or Placebo in Combination with Gemcitabine for the First‐Line Treatment of Pancreatic Adenocarcinoma

Z. Wainberg, J. Bendell, Hua Dong, 2017, The oncologist.

A Phase 2 Study of 5-Fluorouracil (5-FU), Ziv-Aflibercept, and Radiation for the Preoperative and Adjuvant Treatment of Patients with Stage II/III Rectal Cancer

J. Bendell, A. Kennedy, B. Hemphill, 2017, Cancer investigation.

A phase I study of bevacizumab (BV) plus ABT-510 in patients with advanced solid tumors

H. Hurwitz, J. Bendell, M. Morse, 2007 .

A Phase II Study of FOLFOXIRI Plus Panitumumab Followed by Evaluation for Resection in Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only

J. Bendell, M. Moskowitz, D. Waterhouse, 2016, The oncologist.

Concurrent chemoradiotherapy in resected extrahepatic cholangiocarcinoma.

C. Willett, R. Clough, H. Hurwitz, 2009, International journal of radiation oncology, biology, physics.

Population pharmacokinetics of PEGylated liposomal CPT-11 (IHL-305) in patients with advanced solid tumors

Suzanne F. Jones, J. Bendell, H. Burris, 2013, European Journal of Clinical Pharmacology.

Results of the X-PECT study: A phase III randomized double-blind, placebo-controlled study of perifosine plus capecitabine (P-CAP) versus placebo plus capecitabine (CAP) in patients (pts) with refractory metastatic colorectal cancer (mCRC).

N. Senzer, J. Bendell, A. Lockhart, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I/II Study to Assess the Safety, Pharmacokinetics (PK) and Efficacy of Lorvotuzumab Mertansine (LM, IMGN901) in Combination with Carboplatin/Etoposide in Patients with Solid Tumors Including Small-Cell Lung Cancer (SCLC)

A. Argiris, J. Bendell, A. Mita, 2012 .

First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer

G. Shapiro, J. Tabernero, E. Kwak, 2015, Clinical Cancer Research.

First-line durvalumab + monalizumab, mFOLFOX6, and bevacizumab or cetuximab for metastatic microsatellite-stable colorectal cancer (MSS-CRC).

G. Curigliano, N. Segal, Z. Wainberg, 2020 .

Evofosfamide (TH-302) in combination with gemcitabine in previously untreated patients with metastatic or locally advanced unresectable pancreatic ductal adenocarcinoma: Primary analysis of the randomized, double-blind phase III MAESTRO study.

H. Lenz, J. Tabernero, J. Furuse, 2016 .

Y. Bang, J. Bendell, M. Alsina, 2014 .

Two randomized, placebo-controlled phase 3 studies of ruxolitinib (Rux) + capecitabine (C) in patients (pts) with advanced/metastatic pancreatic cancer (mPC) after failure/intolerance of first-line chemotherapy: JANUS 1 (J1) and JANUS 2 (J2).

M. Hidalgo, H. Hurwitz, C. Verslype, 2017 .

Efficacy/safety analysis of a phase 2 study of ruxolitinib (Rux) + regorafenib (Re) in patients (pts) with relapsed/refractory (r/r) metastatic colorectal cancer (mCRC).

J. Nemunaitis, J. Bendell, C. Borg, 2017 .

mTOR inhibitor everolimus (Ev) and IGFR inhibitor OSI-906 (OSI) for the treatment of patients (pts) with refractory metastatic colorectal cancer (mCRC): A Sarah Cannon Research Institute phase I trial.

L. Hart, J. Bendell, H. Burris, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A First-in-Human Phase I Study to Evaluate the ERK1/2 Inhibitor GDC-0994 in Patients with Advanced Solid Tumors

Sandra M. Sanabria-Bohórquez, P. LoRusso, J. Soria, 2019, Clinical Cancer Research.

A phase Ib study of the MEK inhibitor GSK1120212 combined with gemcitabine in patients with solid tumors: Interim results.

A. Tolcher, A. Patnaik, J. Bendell, 2011, Journal of Clinical Oncology.

Abstract CT136: Final biomarker analysis of the phase I study of the selective BRAF V600 inhibitor encorafenib (LGX818) combined with cetuximab with or without the α-specific PI3K inhibitor alpelisib (BYL719) in patients with advanced BRAF-mutant colorectal cancer

S. Jaeger, J. Schellens, H. Lenz, 2015 .

Abstract 3276: A Phase 1 dose escalating study with ACE-041, a novel inhibitor of ALK1 mediated angiogenesis, in patients with advanced solid tumors

H. Hurwitz, Sunil Sharma, J. Bendell, 2011 .

Phase I study of ACE-041, a novel inhibitor of vascular maturation, in patients with advanced solid tumors or relapsed/refractory multiple myeloma.

H. Hurwitz, N. Solban, J. Bendell, 2010 .

A phase I/II, two-part, multicenter, first-in-human study of DS-7300a in patients with advanced solid malignant tumors.

Toshio Shimizu, J. Bendell, S. Piha-Paul, 2020 .

Pen-866, a miniature drug conjugate of a heat shock protein 90 (HSP90) ligand linked to SN38 for patients with advanced solid malignancies: Phase I and expansion cohort results.

J. Bendell, G. Falchook, Anish Thomas, 2020 .

Abstract PR08: Antitumor activity and immune correlates of PEGylated human IL-10 (AM0010) alone or in combination with anti-PD-1

J. Hecht, K. Papadopoulos, A. Patnaik, 2016 .